Cardiology
Conditions
Interventions
Amlodipine
Hydrochlorothiazide
Sponsors
Ejiroghene Umuerri
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 35 - 65 years Systolic blood pressure of 140mmHg and above and less than 180mmHg
Exclusion criteria
Exclusion criteria: Participants with severe hypertension (BP =180/110mmHg) Patients with suspected secondary hypertension Participants with a history of use of antihypertensive medications, statins, anti-platelets, and vitamin C supplements in the past three months before the screening date. Participants with eGFR<35ml/min/1.73m2, congestive cardiac failure, transient ischaemic attack or stroke, acute or chronic coronary syndrome, and hepatic failure. Participants with mental impairment capable of interfering with the conduct of the study. Pregnant women and women of childbearing age who are not on effective contraception. Unwillingness to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in levels of oxidative stress biomarkers, malondialdehyde (MDA) and superoxide dismutase (SOD) from baseline to 8 weeks of study drug use. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in systolic and diastolic BP after use of amlodipine for eight weeks.;Differences in blood pressure (SBP and DBP), estimated glomerular filtration rate (eGFR), fasting blood glucose (FBS) and fasting serum lipid profile (FSLP) between the study group and control | — |
Countries
Nigeria
Contacts
Public ContactAfeyodion Akhator
Chairman DELSUTH HREC
Outcome results
None listed